



# Duke Cardio-Oncology news

A joint publication of the Duke Cancer Institute  
and the Duke Division of Cardiology

Issue 1 | August 2015

## What is cardio-oncology?

Cardio-oncology is the evolving discipline focused on the intersection of cardiovascular disease (CVD) and cancer.



Cardiovascular diseases increase the risk of complications of cancer treatment, and cancer treatment itself can cause cardiovascular diseases. On average, **20% of patients receiving certain classes of anticancer therapies may**

**experience cardiac adverse effects** that manifest as either an acute toxic effect or potentially a late complication.

On the flip side, pre-existing cardiac conditions or risk factors may limit available therapeutic options for cancer treatment.

Some of the same factors cause both cardiovascular disease and


cancer. For the first time, clinicians and researchers are starting to link these previously unrelated diseases.



# Why is cardio-oncology important?

The National Cancer Institute reports 41% of cancer survivors live 10 years or more, and 15% live 20 years or more. After secondary malignancies, cardiovascular issues are the leading cause of late morbidity and death among cancer survivors. Also, to help more patients become cancer survivors, understanding how cardiovascular disease contributes to response to cancer treatment is important. There is an urgent need for oncologists, cardiologists, and basic and population science researchers to be more proactive

in developing strategies to work together to understand how best to treat the whole patient, one who can be affected by both cardiovascular disease and cancer.



## What is happening at Duke?

A cardio-oncology working group formed in late 2014 at Duke University as a joint collaboration of cardiologists and oncologists who share a similar interest in cardio-oncology. The group has worked diligently on identifying priorities and tasks in diverse areas of need. The goal of the group is to create a foundation that will allow for

the development of a full cardio-oncology program at Duke. Faculty involved in the cardio-oncology working group are Drs. Chiara Melloni, Michel Khouri, and Pamela Douglas (Department of Cardiology); Drs. James Abbruzzese, Gretchen Kimmick, Michael Harrison, Steven Patierno, and Kathryn Pollak (Duke Cancer Institute); and Dr. Michaela Dinan

(health service research, Duke Clinical Research Institute, Duke Cancer Institute).

**The cardio-oncology working group will host its first Duke Cardio-Oncology Symposium on Saturday, March 5th, 2016.**



# Recent publications

O'Farrell S, Garmo H, Holmberg L, Adolffson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. *J Clin Oncol.* 2015;33:1243-51.

PMID: [25732167](#).


Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. *Circulation.* 2015;131:1981-8. PMID: [25948538](#).

Harshman LC, Wang X, Nakabayashi M, Xie W, Valenca L, Werner L, Yu Y, Kantoff AM, Sweeney CJ, Mucci LA, Pomerantz M, Lee GSM, Kantoff PW. Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. *JAMA Oncol.* 2015;1:495-504.

Cardwell CR, Mc Menamin Ú, Hughes CM, Murray LJ. Statin use and survival from lung cancer: a population-based cohort study. *Cancer Epidemiol Biomarkers Prev.* 2015;24:833-41. PMID: [25934831](#).

Chavez-MacGregor M, Niu J, Zhang N, Elting LS, Smith BD, Banchs J, Hortobagyi GN, Giordano SH. Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older patients with breast cancer. *J Clin Oncol.* 2015;33:2176-83. PMID: [25964256](#).

Hess CN, Roe MT, Clare RM, Chiswell K, Kelly J, Tchong JE, Hagstrom E, James SK, Khouri MG, Hirsch BR, Kong DF, Abernethy AP, Krucoff MW. Relationship between cancer and cardiovascular outcomes following percutaneous coronary intervention. *J Am Heart Assoc.* 2015;4:pii:e001779. PMID: [26150477](#).



# Upcoming events

## First Global Cardio-Oncology Summit

Thursday–Friday,  
October 15–16, 2015

Nashville, TN

[http://cardiaconology.ca/  
current-conference/](http://cardiaconology.ca/current-conference/)

## Boot Camp in Onco-Cardiology

Saturday, November 14, 2015

8 am to 5 pm

MD Anderson Cancer Center,  
University of Texas, Houston, TX

## First Duke Cardio-Oncology Symposium

Saturday, March 5, 2016

8 am to 5 pm

Durham, NC



Canadian Cardiac  
Oncology Network

INTERNATIONAL  
**CardiOncology**  
SOCIETY



## Useful links

[icosna.org](http://icosna.org)

[cardio-onc.org](http://cardio-onc.org)

## Contact us

**Chiara Melloni, MD, MHS**

Assistant Professor of Medicine  
Duke Clinical Research Institute  
[chiara.melloni@duke.edu](mailto:chiara.melloni@duke.edu)